Dr John H Kim, MD | |
17638 140th Ave Ne, Woodinville, WA 98072-6800 | |
(425) 485-4100 | |
Not Available |
Full Name | Dr John H Kim |
---|---|
Gender | Male |
Speciality | Internal Medicine |
Location | 17638 140th Ave Ne, Woodinville, Washington |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1154596740 | NPI | - | NPPES |
1154596740 | Medicaid | WA | |
0297258 | Other | L&I |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207R00000X | Internal Medicine | MD60294832 (Washington) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr John H Kim, MD Po Box 50095, Seattle, WA 98145-5095 Ph: (206) 543-6420 | Dr John H Kim, MD 17638 140th Ave Ne, Woodinville, WA 98072-6800 Ph: (425) 485-4100 |
News Archive
vTv Therapeutics LLC today announced enrollment of the first patients into STEADFAST (Single Trial Evaluating Alzheimer's Disease Following Addition to Symptomatic Therapy), vTv's Phase 3 placebo controlled trial of azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE) for treatment of mild Alzheimer's disease.
The Obama administration granted another 106 waivers last month from part of the health care reform law -; the first round of three-year waivers the Health and Human Services Department has approved. The new approvals bring the total number of waivers to 1,472, according to HHS. Those figures cover waivers granted through the end of July.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has entered into a scientific collaboration with University of California, Los Angeles to research the conversion of dermal fibroblasts into pure functional human cell types that may have greater regenerative capacity.
OSI Pharmaceuticals, Inc. has announced further results from the Phase III SATURN study showing that Tarceva® (erlotinib) extended the survival of patients with advanced non-small cell lung cancer (NSCLC) when used as single agent, maintenance therapy in patients who did not progress following first-line treatment with platinum-based chemotherapy.
› Verified 7 days ago
Karen Sonhee Kim, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 16916 140th Ave Ne Ste 300, Woodinville, WA 98072 Phone: 425-481-6363 | |
Dr. William Griffith Couser, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 16050 169th Ave Ne, Woodinville, WA 98072 Phone: 425-415-8436 Fax: 425-949-8438 | |
Dr. Virginia Teresa Stevens, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 14024 Ne 181st St, Woodinville, WA 98072 Phone: 425-424-3416 Fax: 425-424-3685 | |
Prachi R Munshi, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 17638 140th Ave Ne, Woodinville, WA 98072 Phone: 425-485-4100 | |
Dr. Ahana Roy, MD FACP Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 17638 140th Ave Ne, Woodinville, WA 98072 Phone: 206-520-5000 |